Key result
Increasing anemia severity is linked to a higher likelihood of chemotherapy delay in breast cancer.
Why the study?
Anemia frequently complicates breast cancer chemotherapy and may compromise treatment delivery, especially in resource-limited government oncology centers where diagnostic tests are constrained.
Observational (n=85)
No
In a resource-limited government oncology center, anemia-related chemotherapy delays were infrequent (5.9%) and management strategies were largely driven by anemia severity rather than comprehensive etiologic evaluation.
Answers are grounded in this paper and cite their sources.
Describes real-world anemia patterns and practices in resource-limited breast cancer care; leaves open optimal evaluation strategies for prospective validation.
Objectives: Anemia is a common complication among patients receiving systemic chemotherapy for breast cancer and may adversely affect treatment delivery, particularly in resource-limited settings. In many government oncology centers, anemia evaluation is frequently constrained by the limited availability and affordability of diagnostic tests. This study aimed to describe anemia-related chemotherapy outcomes and real-world anemia management practices among breast cancer patients treated at a tertiary government hospital. Material and Methods: This retrospective audit reviewed medical records of breast cancer patients with documented anemia (hemoglobin <12.0 g/dL) who received systemic chemotherapy at the Tumor Clinic of East Avenue Medical Center from July to December 2021. Patient demographics, disease stage, chemotherapy regimens, anemia severity, supportive interventions, and chemotherapy outcomes (continued versus delayed) were collected. Anemia severity was classified using World Health Organization (WHO) hemoglobin thresholds for non-pregnant women: mild (11.0–11.9 g/dL), moderate (8.0–10.9 g/dL), and severe (<8.0 g/dL). Associations were explored using chi-square or Fisher’s exact tests. Results: A total of 85 patients were included, most of whom had stage III disease and received anthracycline-based chemotherapy. Anemia-related chemotherapy delay occurred in 5.9% of patients. No significant associations were observed between chemotherapy delay and age, cancer stage, chemotherapy regimen, or phase of chemotherapy. Analysis of 328 anemia episodes demonstrated that increasing anemia severity was associated with escalation of supportive interventions, including erythropoiesis-stimulating agents and blood transfusion, and with a higher likelihood of chemotherapy delay ( p <0.001). Mild anemia was generally managed conservatively without treatment interruption, while moderate and severe anemia prompted more intensive interventions. Iron studies, vitamin B12 levels, and reticulocyte counts were not routinely performed in the majority of patients, reflecting real-world resource limitations during the study period. Conclusion: Anemia-related chemotherapy delays were infrequent in this cohort. Management strategies largely reflected anemia severity rather than patient or treatment characteristics. This study highlights existing supportive care practices and diagnostic limitations in a government-funded oncology center and underscores the need for standardized anemia evaluation pathways in resource-constrained settings.
No takes yet. Share an insight, caveat, or question.
Amadore et al. (2026) conducted an observational in Breast cancer with anemia (n=85). Anemia severity was evaluated on Anemia-related chemotherapy delay (p=<0.001). Increasing anemia severity in breast cancer patients receiving chemotherapy was associated with a higher likelihood of chemotherapy delay, which occurred in 5.9% of patients overall.
Synapse has enriched 10 related papers. Consider them for comparative context: